| __timestamp | ADMA Biologics, Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 14562000000 |
| Thursday, January 1, 2015 | 4311461 | 16188000000 |
| Friday, January 1, 2016 | 6360761 | 17183000000 |
| Sunday, January 1, 2017 | 29164321 | 17632000000 |
| Monday, January 1, 2018 | 42194635 | 17617000000 |
| Tuesday, January 1, 2019 | 39504238 | 20088000000 |
| Wednesday, January 1, 2020 | 61291426 | 20932000000 |
| Friday, January 1, 2021 | 79769341 | 23658000000 |
| Saturday, January 1, 2022 | 118814535 | 28448000000 |
| Sunday, January 1, 2023 | 169273000 | 35765000000 |
| Monday, January 1, 2024 | 44522000000 |
Unleashing the power of data
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial. Novo Nordisk A/S, a leader in diabetes care, and ADMA Biologics, Inc., a niche player in immunotherapy, present contrasting financial narratives from 2014 to 2023. Novo Nordisk's cost of revenue surged by 145%, reflecting its expansive growth and market dominance. In contrast, ADMA Biologics experienced a staggering 4,420% increase, highlighting its aggressive scaling strategy. By 2023, Novo Nordisk's cost of revenue was approximately 211 times that of ADMA, underscoring its vast operational scale. This decade-long analysis reveals not just financial figures but strategic insights into how these companies navigate the competitive landscape. As the biopharma sector evolves, such financial insights are invaluable for investors and industry watchers alike.
Cost Insights: Breaking Down Novo Nordisk A/S and Johnson & Johnson's Expenses
Cost of Revenue Trends: Novo Nordisk A/S vs Merck & Co., Inc.
Cost of Revenue Comparison: Novo Nordisk A/S vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Cost Insights: Breaking Down Novo Nordisk A/S and Walgreens Boots Alliance, Inc.'s Expenses
Cost of Revenue Comparison: Novo Nordisk A/S vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Novo Nordisk A/S vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Catalent, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited